250651-04-8

Basic information

• Product Name: 3-amino-2,4,6-trimethylbenzonitrile
• Synonyms: 3-amino-2,4,6-trimethylbenzonitrile
• CAS NO: 250651-04-8
• Molecular Weight: 160.219
• Mol File: 250651-04-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-amino-2,4,6-trimethylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-2,4,6-trimethylbenzonitrile(250651-04-8)
• EPA Substance Registry System: 3-amino-2,4,6-trimethylbenzonitrile(250651-04-8)

Safety Data

• Hazardous Substances Data: 250651-04-8(Hazardous Substances Data)

Upstream product

• 82842-52-2 3-bromo-2,4,6-trimethylaniline 
• 40188-34-9 2,4,6-trimethylbenzaldehyde oxime 
• 2571-52-0 cyanomesitylene 
• 250651-03-7 2,4,6-trimethyl-3-nitro-benzonitrile 

Relevant articles and documents

Light-Emitting Element, Display Device, Electronic Device, and Lighting Device

A light-emitting element with high emission efficiency. The light-emitting element includes a first organic compound, a second organic compound, and a guest material. The LUMO level of the first organic compound is lower than the LUMO level of the second organic compound. The HOMO level of the first organic compound is lower than the HOMO level of the second organic compound. The HOMO level of the guest material is higher than the HOMO level of the second organic compound. The energy difference between the LUMO level of the guest material and the HOMO level of the guest material is larger than the energy difference between the LUMO level of the first organic compound and the HOMO level of the second organic compound. The guest material has a function of converting triplet excitation energy into light emission. The first organic compound and the second organic compound form an exciplex.

Endothelin antagonists: Substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors

We have previously disclosed the discovery of 2,4-disubstituted anilinothiophenesulfonamides with potent ET(A)-selective endothelin receptor antagonism and the subsequent identification of sitaxsentan (TBC11251, 1) as a clinical development compound (Wu et al. J. Med. Chem. 1997, 40, 1682 and 1690). The orally active 1 has demonstrated efficacy in a phase II clinical trial of congestive heart failure (Givertz et al. Circulation 1998, 98, Abstr. 3044) and was active in rat models of myocardial infarction (Podesser et al. Circulation 1998, 98, Abstr. 2896) and acute hypoxia-induced pulmonary hypertension (Chen et al. FASEB J. 1996, 10 (3), A104). We now report that an additional substituent at the 6-position of the anilino ring further increases the potency of this series of compounds. It was also found that a wide range of functionalities at the 3-position of the 2,4,6-trisubstituted ring increased ETA selectivity by ~10-fold while maintaining in vitro potency, therefore rendering the compounds amenable to fine-tuning of pharmacological and toxicological profiles with enhanced selectivity. The optimal compound in this series was found to be TBC2576 (7u), which has ~10- fold higher ETA binding affinity than 1, high ET(A)/ET(B) selectivity, and a serum half-life of 7.3 h in rats, as well as in vivo activity.